Company Overview of VBI Vaccines Inc
VBI Vaccines Inc. operates as a biopharmaceutical company in the United States. It develops eVLP vaccine platform that allows for the design of enveloped (“e”) virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It is also developing a thermostable technology platform that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. The company was formerly known as Paulson Capital (Delaware) Corp and changed its name to VBI Vaccines Inc. in July 2014. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
222 Third Street
Cambridge, MA 02142
Key Executives for VBI Vaccines Inc
Chief Executive Officer, President and Director
Total Annual Compensation: $350.0K
Chief Financial Officer
Total Annual Compensation: $198.0K
Senior Vice President of Research
Total Annual Compensation: $220.0K
Vice President of Formulation Development
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2013.
VBI Vaccines Inc Key Developments
VBI Vaccines, Inc. Announces New Data Supporting the Manufacture of Prophylactic CMV Vaccine Candidate
Apr 9 15
VBI Vaccines Inc. provided an update on the progress of its cytomegalovirus vaccine development program on April 8, 2015 at the World Vaccine Congress 2015 in Washington, D.C. Dr. David E. Anderson, company's Senior Vice President of Research, presented new data from interim yield and purity testing of VBI-1501A, company's prophylactic CMV vaccine candidate, which is now being manufactured in quantities needed for planned toxicology, stability, and clinical studies. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines. eVLPs are a new class of vaccines that are designed to resemble the structure of viruses, but do not contain any potentially infectious viral material. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone. During recent testing, the company employed electron microscopy to confirm the integrity of the eVLP particles (drug substance) used to create VBI-1501A. A separate in vivo potency assay assessed the consistency and potency of multiple batches of VBI-1501A, with positive interim results. Purity measurements are expected to meet regulatory requirements for clinical evaluation of the vaccine candidate. The company plans to initiate formal toxicology studies in the second quarter of 2015.
VBI Vaccines Inc. enters into research collaboration with Sanofi Pasteur
Apr 6 15
VBI Vaccines Inc. announced that it entered into a research collaboration with Sanofi Pasteur to develop a more stable version of a key Sanofi Pasteur vaccine candidate using its Lipid Particle Vaccine formulation technology. VBI Vaccines announced that the collaboration agreement provides Sanofi Pasteur with an option to acquire certain worldwide rights to use the LPV technology in its vaccines.
VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM
Jan 6 15
VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Jeff Baxter, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries